UK-based pharmaceutical company Diurnal has collaborated with Clinigen’s IDIS managed access unit to introduce a patient access programme for the former’s Infacort and Chronocort to European patients with cortisol deficiency disorders.

The programme will allow physicians to prescribe the products before the European approval and commercial launch, as unlicensed medicines on a named patient basis for patients who do not have any other treatment options.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Diurnal chief executive officer Martin Whitaker said: “Our first product, Infacort, is currently undergoing regulatory review with the EMA.

“Whilst this is ongoing, we are focused on putting in place the appropriate infrastructure to ensure that patients with cortisol deficiency but no other treatment options can access this medicine as efficiently as possible.

“Our first product, Infacort, is currently undergoing regulatory review with the EMA.”

“As a global leader in providing unlicensed medicines to patients on a named patient basis, Clinigen is well placed to help us make Infacort and Chronocort accessible to patients ahead of their potential approval.”

Infacort is a hydrocortisone preparation designed for use in children with adrenal insufficiency (AI), or congenital adrenal hyperplasia (CAH), while Chronocort is a modified release hydrocortisone preparation developed to provide a circadian rhythm similar to cortisol for the treatment of adult CAH.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

According to Clinigen, its international reach can be leveraged to provide the unlicensed medicines to the patients quickly, safely and ethically.

A paediatric use marketing authorisation (PUMA) application for Infacort has been submitted to the European Medicines Agency last year and Chronocort is currently undergoing a Phase III clinical trial.